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Today due to improvements in cancer treatment there is an increasing number of long-term cancer survivors, many of whom suffer 
from infertility caused by malignancy itself and chemo- or radiotherapy. Also, anticancer therapy may cause myelosuppression. 
Presently granulocyte colony stimulating factor (G-CSF) is used for prevention and treatment of myelosuppression. Another treat-
ment option used to decrease intoxication and ameliorate side effects of cancer therapy is sorption technology. The aim of our 
investigation was to study the efficiency of combined use of enterosorption and G-CSF to decrease gonadal toxicity of chemo-
therapy. Materials and Methods: Melphalan (L-PAM) injected i.v. at a single dose of 4 mg/kg to white inbred rats was used 
as gonadotoxic and myelosuppressing agent. Carbon enterosorbent C2 was administered by intragastric route as a suspension 
in saline at a dose of 5 ml per 1 kg of rats’ body weight (or 900 mg/kg of the dry mass of enterosorbent) daily for 3 days before and 
for 7 days after L-PAM injection. G-CSF was injected once a day for 4 days starting from the next day after L-PAM administra-
tion at a dose of 50 µg/kg. Histological preparations of testicular tissues were examined by light microscopy. Results: Our findings 
have shown that melphalan caused marked damage of testicular tissues and seminiferous, especially spermatogenic epithelium. The 
most expressed protection of the histological structure of testes was observed when enterosorbent and G-CSF were used in com-
bination. Conclusion: Gonadal toxicity of chemotherapy could be efficiently decreased by the combined use of enterosorption and 
G-CSF.
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In last decades, the modern methods of cancer 
treatment, the newest anti-neoplastic drugs and early 
detection of malignancy have significantly increased 
the number of long-term cancer survivors world-
wide [1–3]. Up to 8 out of 10 children and adolescents 
live longer than 5 years after the cancer diagnosis [4]. 
Most of them experience a range of negative out-
comes, in particular, infertility problem.
Gonadal toxicity in cancer patients could result from 
tumor growth, or be a consequence of hormonal and 
metabolic alterations, or chemo- and radiotherapy. 
The approved methods to preserve fertility in cancer 
patients prior to treatment include semen/oocytes 
cryopreservation and testicular/ovarian ultra-fast freez-
ing following with in vitro fertilization or intracytoplasmic 
sperm injection to achieve the result [5–7]. For most 
females oocyte banking is feasible even prior to pu-
berty onset. Males can use sperm banking only after 
13–14 years of age, when spermatogenesis has started. 
Prepubertal testicles are more vulnerable to cytotoxic 
effects of chemotherapy than the adult testes [3]. For 
males with cancer even sperm banking could not guar-
antee the future fatherhood. Nearly 70% of samples 
taken before treatment already contain abnormalities 
of spermatozoa, while nearly 12–15% of patients suf-
fer from azoospermia at the tieme of diagnosis, which 
makes cryopreservation impossible [3]. In these situa-
tions, there are some experimental methods to preserve 
fertility: spermatogonial stem cell transplantation, tes-
ticular allografting and harvesting of germinal cells [3, 
8]. These methods, however, are not yet approved for 
humans and carry some technical and ethical problems. 
Thus, there is still a need for effective methods to pre-
serve fertility in long-term cancer survivors.
Cancer treatment methods such as whole-body 
irradiation, the use of cytostatics, especially alkylating 
agents, and surgical removal of reproductive organs 
have the highest negative impact on spermatogenetic 
potential and ovarian follicular function. The risks in-
crease with younger age at the time of treatment, 
higher cumulative dose and the use of combined-
modality therapy [14, 15]. Alkylating agents, especially 
nitrogen mustard derivates, are among anti-cancer 
medications that have the highest potential to cause 
problems with fertility, up to sterility (Table), depending 
on the age of patient [3].
Table. Potential to impair spermatogenesis for some chemotherapeutic 
medications
High potential Medium potential Low potential
Cyclophosphamide,  
ifosfamide,  
chlormethine,  
busulfan,  
melphalan,  
procarbazine,  
dacarbazine,  
chlorambucil
Cisplatin,  
carboplatin,  
doxorubicin
Vincristine,  
methotre xate dactinomycin, 
bleomycin,
mercaptopurine,  
vinblastine
Enteral sorption therapy (enterosorption) is widely 
used today to decrease manifestations of systemic 
acute and chronic intoxications, oxidative stress in ca-
ses of renal failure, hepatic insufficiency, burn toxico-
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sis, acute enteric infections [9]. Sorption technologies 
are also used to decrease endogenic intoxication 
during treatment of malignancies [10–12]. We have 
previously demonstrated promising results concerning 
protective properties of enterosorption with the use 
of carbon sorbent counteracting myelosuppression, 
an acute dose-limiting and sometimes life-threatening 
complications of treatment [13]. We have found that 
bone marrow protection was the most effective when 
enterosorption was used together with granulocyte 
colony stimulating factor (G-CSF) [13]. The aim of this 
investigation was to study the possibilities of such 
combination to preserve spermatogenesis during 
chemotherapy with an alkylating agent.
MATERIALS AND METHODS
The study was carried out on 40 white inbred rats 
weighting 200 ± 20 g housed in the vivarium of R.E. Ka-
vetsky Institute of Experimental Pathology, Oncology 
and Radiobiology (IEPOR). The use and care of the 
experimental animals have been performed in accor-
dance with the standard international rules of biologic 
ethics and were approved by Institutional Animal Care 
and Use Committee. To examine and study gonadal 
toxicity we used alkylating agent melphalan (L-PAM, 
Alkeran, GlaxoSmithKline, Great Britain). Animals were 
randomly distributed into 4 groups (n = 10): 1) intact 
rats; 2) rats treated with L-PAM; 3) rats treated with 
both L-PAM and carbon enterosorbent C2 (L-PAM + 
C2); 4) rats treated with L-PAM, C2 and G-CSF filgras-
tim (L-PAM + C2 + filgrastim).
L-PAM was injected single-dose in the tail vein 
at a dose of 4.0 mg/kg. Filgrastim (Neupogen, Hoff-
man-La Roche Ltd., Switzerland) is a G-CSF analogue 
produced by recombinant DNA technology and used 
to stimulate proliferation and differentiation of granulo-
cytes. It was injected once a day starting from the next 
day after L-PAM administration for 4 days at a dose 
of 50 �g/kg.
Carbon granulated enterosorbent C2, produced 
by IEPOR, has the following parameters: bulk density 
of γ = 0.18 g/cm3, granule diameter of 0.15 to 0.25 mm, 
BET pore (Brunauer — Emmett — Teller model of pore 
distribution calculation) surface 2162 m2/g. The ad-
ministered dose of C2 was 5 ml per 1 kg of rat’s body 
weight (or 900 mg/kg of the dry mass of enterosor-
bent). A suspension of sorbent in appropriate volume 
of distilled water was introduced via the tube into rat 
stomach once a day for 3 days before the day of L-PAM 
injection and for 7 days after injection. Rats of L-PAM- 
and intact groups were given equivalent volume of dis-
tilled water. Animals of intact group instead of L-PAM 
received intravenously equal volume of saline.
On the 8th day after L-PAM injection, the rats were 
weight and sacrificed using ketamine hydrochloride 
general anesthesia. Testicular tissues were taken for 
histological analysis. Tissues were fixed in formalin, 
paraffin embedded and sectioned according to the 
standard technique. Serial 5 μm sections were stained 
with hematoxylin and eosin and examined by light mi-
croscopy using Genetic Pro Bino microscope (Delta 
Optical). Representative areas of the samples were 
microphotographed using ×10 and ×20 objectives 
using SCMOS Digital Camera and ToupView software 
with different magnification.
RESULTS AND DISCUSSION
Histological structure of the testis of an intact rat 
is presented in Fig. 1. All tubules have round shape and 
mostly 3–5 layers of germinal (seminiferous epithe-
lium), which contains spermatogenic and Sertoli cells. 
Primary and secondary spermatocytes are located 
near basal membranes with darker nuclei. Spermatids 
and mature spermatozoa can be observed inside the 
lumen in appropriate quantities.
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Fig. 1. Histological structure of intact rat testis. H&E, × 200 (1 — 
mature spermatozoa; 2 — seminiferous epithelium; 3 — intersti-
tial Leydig cell; 4 — sertoli cells)
In histological samples of the animals treated 
with L-PAM (Fig. 2, a) were observed the following 
structural chan ges in comparison to the intact group: 
deformation of the seminiferous tubules and marked 
enlargement of seminiferous tubules lumens; reduc-
tion and disorganization in the spermatogenic layers 
of epithelium (1), accompanied with sharp reduction 
in the number of luminal spermatozoa (2); empty 
lumens (3). Simultaneously, in seminiferous tubules 
which still preserved the large number of mature 
spermatozoa, there were observed detachment and 
damage of primary and secondary spermatocytes and 
spermatids (4) (Fig. 2, b).
In rats treated with both enterosorbent C2 and 
melphalan, some restoration of seminiferous epithe-
lium and its layers could be observed, however, it did 
not occur in all seminiferous tubules (Fig. 3). Also, the 
increased number of luminal spermatids and sperma-
tozoa was observed.
Maximal improvement of histological structures 
of L-PAM-affected testis was seen when enterosor-
bent C2 and G-CSF were administered simultaneously. 
Repair of epithelial layers was detected in almost all 
of seminiferous tubules (Fig.4).
Gonadotoxicity of melphalan is caused by both 
direct and indirect mechanisms. Active metabolites 
of the medication form cross-links with DNA and inhibit 
its synthesis and function, which leads to apoptotic 
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cell death [16]. Melphalan also causes direct partial 
destruction of gonadal tissues [17]. Like all alkylating 
agents, it has radiomimetic properties and causes 
intensive oxidative stress, forming reactive oxygen 
species which cause indirect damage of seminiferous 
epithelium [18].
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Fig. 2. Histological structure of testis of L-PAM treated rats. 
H&E, ×100. Description is in the text
Fig. 3. Histological structure of testis of a rat from L-PAM + 
C2 — treated group. H&E, × 100
I n  c o n c l u s i o n ,  m e l p h a l a n  a t  a  d o s a g e 
of 4 mg/kg causes marked changes in histologic 
structures of rat testes, including deformation of semi-
niferous epithelium, reduction and disorganization 
of spermatogenic epithelium with its maturing forms and 
spermatozoa. Enterosorption with carbon enterosorbent 
C2 decreases the damage of testicular tissues and in-
creases the number of spermatocytes, spermatids and 
spermatozoa in the large part, but not all seminiferous 
tubules. Maximal positive histological improvements 
of the testicular structures are observed when entero-
sorption and G-CSF are administered together.
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Fig. 4. Histological structure of testis of rats from L-PAM + C2 + 
filgrastim — treated group. H&E, × 100
Preservation of fertility in cancer patients becomes 
an important issue because of steadily increasing 
number of cancer survivors. The positive effects 
of combined use of carbon enterosorbent and G-CSF 
reported in this study point to the need for further func-
tional investigation and subsequent implementation 
of these results into clinical practice.
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